Vanguard Group Inc. increased its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 18.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 871,510 shares of the company’s stock after purchasing an additional 134,165 shares during the period. Vanguard Group Inc. owned 2.51% of Galectin Therapeutics worth $2,144,000 as of its most recent SEC filing.
Separately, Northern Trust Corp boosted its stake in Galectin Therapeutics by 4.4% during the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after purchasing an additional 3,176 shares during the period. 11.07% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently weighed in on GALT shares. ValuEngine cut shares of Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 21st. Seaport Global Securities reiterated a “buy” rating and set a $5.00 price target on shares of Galectin Therapeutics in a research note on Friday, October 6th. Roth Capital started coverage on shares of Galectin Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $8.00 price target for the company. HC Wainwright increased their price target on shares of Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Finally, Zacks Investment Research upgraded shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Thursday, November 30th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $4.55.
Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) opened at $2.01 on Friday. Galectin Therapeutics Inc. has a 52 week low of $0.87 and a 52 week high of $3.68.
Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Tuesday, November 7th. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. research analysts predict that Galectin Therapeutics Inc. will post -0.52 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Vanguard Group Inc. Acquires 134,165 Shares of Galectin Therapeutics Inc. (GALT)” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.thestockobserver.com/2017/12/08/vanguard-group-inc-acquires-134165-shares-of-galectin-therapeutics-inc-galt.html.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.